P3355
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda InterferonPhase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for ProgeriaStudy of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the LiverLonafarnib for Chronic Hepatitis DPredicting Response and Toxicity in Patients Receiving Lonafarnib for Breast CancerLonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid LaminopathyStudy of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2aCombination Chemotherapy in Treating Patients With Advanced Cancer (1999-04-30)
P4844
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatmentThe FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.Lonafarnib is a potential inhibitor for neovascularization.Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.Lonafarnib in cancer therapy.Lonafarnib for cancer and progeria.Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.The prenylation inhibitor, lonafarnib: a new therapeutic strategy against hepatitis delta.High-performance liquid chromatographic analysis of the anti-tumor agent SCH 66336 in cynomolgus monkey plasma and evaluation of its chiral inversion in animals.
P921
Q61907689-396CB033-F688-4FE9-92B3-C36FC187EE83Q61921501-A74E5335-0F44-4E4E-ACA7-4E3A6DAB6923Q62105353-EF198BEA-7243-4303-B997-1B3F30B5C1D0Q62106222-40CE4B31-281F-4C50-850D-A0389128A28AQ62106226-D89CDED6-5F00-4DC8-9B93-5EA011C18BD3Q62110856-172E4FAE-3121-4CF4-89A1-53D6482C685FQ63319381-5F448844-A5C6-484D-B2D0-085424806558Q63340964-C4D650C1-E09E-4A82-9093-98238EA2511CQ63580522-7EC018FB-EA5E-4DFC-BFD3-2773D6AF5B0AQ63811635-4E6D5F57-C84C-4C0C-B894-1420AA9BA86EQ86250147-D3ACAF59-60AD-49EE-8CFE-B9633B8B6B2B
P4844
Q24620393-7EF4B30B-1F1E-4513-BE79-85E61CC2A520Q27853172-5BEDFF62-77AF-4439-9749-3225F141361DQ31711523-A052AEDB-7077-4AAA-984B-09CAB6993B76Q35324064-D19F5738-F32A-4A80-9DDA-EB8F6BCC7EAEQ36428213-643B1FB6-B450-4D14-9710-ECA53D5EEE18Q36491847-14DA20F7-1998-43A1-AFC5-25BA80402BA5Q38012480-6E4EF3AF-1CAB-4E02-BF9A-DF8DFDDF1014Q42538388-CBA7F027-AEAA-4DA7-95A8-040A0D0D6047Q46926433-27C88D56-E60D-4E78-B8EF-2998B079F9B7Q50953485-5D37E58D-238A-45AE-BA93-2C34E98F09E1Q52913246-080530C8-5E94-4D00-B88A-D8A2FC3ECD73
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Lonafarnib
@fr
Lonafarnib
@sh
Lonafarnib
@sr
lonafarnib
@en
لونافارنیب
@azb
لونافارنیب
@fa
ロナファルニブ
@ja
type
label
Lonafarnib
@fr
Lonafarnib
@sh
Lonafarnib
@sr
lonafarnib
@en
لونافارنیب
@azb
لونافارنیب
@fa
ロナファルニブ
@ja
altLabel
4-(2-{4-[(11R)-3,10-dibromo-8- ...... ethyl)piperidine-1-carboxamide
@en
C27H31Br2ClN4O2
@fr
Ionafarnib
@fr
Lonafarnib
@en
SCH 66336
@en
SCH-66336
@en
SCH66336
@en
prefLabel
Lonafarnib
@fr
Lonafarnib
@sh
Lonafarnib
@sr
lonafarnib
@en
لونافارنیب
@azb
لونافارنیب
@fa
ロナファルニブ
@ja
P129
P486
P592
P6366
P638
P661
P662
P665
P683
P1579
P2017
C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(C=C(C=C4CCC5=CC(=CN=C35)Br)Cl)Br)C(=O)N
P2067
P2275
lonafarnib
@en
P231
193275-84-2
P232
P233
C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(C=C(C=C4CCC5=CC(=CN=C35)Br)Cl)Br)C(=O)N
P234
1S/C27H31Br2ClN4O2/c28-20-12-1 ...... H,1-11H2,(H2,31,36)/t25-/m1/s1
P235
DHMTURDWPRKSOA-RUZDIDTESA-N